OncoCyte Total Assets from 2010 to 2025

OCX Stock

USD 2.58 0.06 2.38%

OncoCyte Corp Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 49.1 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

74.7 M

Current Value

70.2 M

Quarterly Volatility

55.2 M

Yuan Drop

Covid

Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 56.8 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0015 or PTB Ratio of 0.64. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.

Check out the analysis of OncoCyte Corp Correlation against competitors.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Latest OncoCyte Corp's Total Assets Growth Pattern

Below is the plot of the Total Assets of OncoCyte Corp over the last few years. Total assets refers to the total amount of OncoCyte Corp assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in OncoCyte Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. OncoCyte Corp's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 74.89 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

OncoCyte Total Assets Regression Statistics

	Arithmetic Mean	40,718,981
	Geometric Mean	22,967,229
	Coefficient Of Variation	109.70
	Mean Deviation	35,114,352
	Median	14,447,000
	Standard Deviation	44,670,531
	Sample Variance	1995.5T
	Range	153.2M
	R-Value	0.71
	Mean Square Error	1053.1T
	R-Squared	0.51
	Significance	0
	Slope	6,683,803
	Total Sum of Squares	29931.8T

OncoCyte Total Assets History

	2025	49.1 M
	2024	86.1 M
	2023	74.9 M
	2022	100.1 M
	2021	159.6 M
	2020	55.4 M
	2019	39.9 M

Other Fundumenentals of OncoCyte Corp

Intangibles To Total Assets

OncoCyte Corp Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Current Deferred Revenue	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		0.95	-0.77	-0.79	0.98	-0.58	0.95	0.85	-0.14	0.91	0.78	0.84	-0.73	0.75	0.67	0.57	0.71	0.91	0.67	0.84	0.81
Total Stockholder Equity	0.95		-0.81	-0.7	0.91	-0.61	0.85	0.89	-0.16	0.82	0.71	0.8	-0.52	0.8	0.74	0.61	0.76	0.97	0.73	0.73	0.69
Net Debt	-0.77	-0.81		0.51	-0.81	0.59	-0.68	-0.96	0.4	-0.67	-0.51	-0.52	0.38	-0.58	-0.4	-0.61	-0.58	-0.75	-0.85	-0.49	-0.68
Retained Earnings	-0.79	-0.7	0.51		-0.8	0.78	-0.86	-0.55	0.44	-0.9	-0.98	-0.96	0.63	-0.76	-0.71	-0.73	-0.77	-0.65	-0.26	-0.96	-0.64
Accounts Payable	0.98	0.91	-0.81	-0.8		-0.6	0.95	0.86	-0.24	0.92	0.79	0.83	-0.74	0.71	0.6	0.59	0.67	0.84	0.67	0.85	0.83
Short Term Investments	-0.58	-0.61	0.59	0.78	-0.6		-0.59	-0.54	0.56	-0.65	-0.77	-0.74	0.2	-0.77	-0.78	-0.93	-0.83	-0.56	-0.26	-0.66	-0.38
Total Liab	0.95	0.85	-0.68	-0.86	0.95	-0.59		0.77	-0.18	0.98	0.88	0.9	-0.85	0.65	0.59	0.58	0.64	0.83	0.55	0.88	0.81
Total Current Assets	0.85	0.89	-0.96	-0.55	0.86	-0.54	0.77		-0.22	0.74	0.56	0.61	-0.46	0.63	0.47	0.56	0.62	0.88	0.9	0.54	0.76
Short Term Debt	-0.14	-0.16	0.4	0.44	-0.24	0.56	-0.18	-0.22		-0.28	-0.44	-0.34	-0.03	-0.29	-0.23	-0.6	-0.35	-0.03	0.03	-0.34	-0.07
Intangible Assets	0.91	0.82	-0.67	-0.9	0.92	-0.65	0.98	0.74	-0.28		0.92	0.92	-0.81	0.66	0.59	0.62	0.67	0.8	0.51	0.9	0.75
Common Stock	0.78	0.71	-0.51	-0.98	0.79	-0.77	0.88	0.56	-0.44	0.92		0.98	-0.63	0.74	0.7	0.73	0.76	0.68	0.27	0.94	0.6
Property Plant Equipment	0.84	0.8	-0.52	-0.96	0.83	-0.74	0.9	0.61	-0.34	0.92	0.98		-0.62	0.79	0.78	0.71	0.8	0.78	0.33	0.94	0.62
Net Tangible Assets	-0.73	-0.52	0.38	0.63	-0.74	0.2	-0.85	-0.46	-0.03	-0.81	-0.63	-0.62		-0.24	-0.22	-0.21	-0.23	-0.51	-0.31	-0.69	-0.69
Long Term Debt	0.75	0.8	-0.58	-0.76	0.71	-0.77	0.65	0.63	-0.29	0.66	0.74	0.79	-0.24		0.84	0.73	0.98	0.76	0.5	0.76	0.48
Short Long Term Debt	0.67	0.74	-0.4	-0.71	0.6	-0.78	0.59	0.47	-0.23	0.59	0.7	0.78	-0.22	0.84		0.78	0.84	0.71	0.2	0.68	0.38
Current Deferred Revenue	0.57	0.61	-0.61	-0.73	0.59	-0.93	0.58	0.56	-0.6	0.62	0.73	0.71	-0.21	0.73	0.78		0.79	0.57	0.27	0.61	0.38
Long Term Debt Total	0.71	0.76	-0.58	-0.77	0.67	-0.83	0.64	0.62	-0.35	0.67	0.76	0.8	-0.23	0.98	0.84	0.79		0.74	0.47	0.74	0.45
Net Invested Capital	0.91	0.97	-0.75	-0.65	0.84	-0.56	0.83	0.88	-0.03	0.8	0.68	0.78	-0.51	0.76	0.71	0.57	0.74		0.73	0.65	0.67
Net Working Capital	0.67	0.73	-0.85	-0.26	0.67	-0.26	0.55	0.9	0.03	0.51	0.27	0.33	-0.31	0.5	0.2	0.27	0.47	0.73		0.3	0.63
Capital Stock	0.84	0.73	-0.49	-0.96	0.85	-0.66	0.88	0.54	-0.34	0.9	0.94	0.94	-0.69	0.76	0.68	0.61	0.74	0.65	0.3		0.66
Net Receivables	0.81	0.69	-0.68	-0.64	0.83	-0.38	0.81	0.76	-0.07	0.75	0.6	0.62	-0.69	0.48	0.38	0.38	0.45	0.67	0.63	0.66

Click cells to compare fundamentals

About OncoCyte Corp Financial Statements

OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	86.1 M	49.1 M
Intangibles To Total Assets	0.68	0.71

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC